Objective:
To emphasize the importance of evaluating glaucoma patients for ocular surface disease (OSD) and proactively managing it to ensure optimal visual outcomes.
Key Findings:
- Over 50% of glaucoma patients experience chronic OSD due to eyedrop therapy, impacting their quality of life.
- Patients with OSD symptoms may have lower adherence to glaucoma medications, leading to worse outcomes.
- Asymptomatic patients can still exhibit corneal staining affecting vision, highlighting the need for routine evaluations.
- Minimally invasive glaucoma surgery (MIGS) offers a less invasive treatment option with fewer complications, making it suitable for many patients.
Interpretation:
Effective management of OSD in glaucoma patients is crucial for maintaining adherence to treatment, improving quality of life, and preventing further ocular complications.
Limitations:
- Access to advanced treatments like platelet-rich plasma drops may be limited, affecting treatment options.
- Not all patients may be candidates for non-drop therapies or MIGS, necessitating individualized treatment plans.
Conclusion:
Screening for OSD should be a standard part of glaucoma management to optimize patient outcomes, and clinicians should consider alternative therapies to reduce reliance on eyedrops while personalizing care.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.